Why did ALZN's EPS remain stagnant throughout 2023?

The EPS of Alzamend Neuro, Inc. (ALZN) remained stagnant throughout 2023 due to a combination of factors related to its financial management and operational focus: 1. **Strategic Focus on Product Development**: Alzamend Neuro has been actively developing its pipeline of products for neurodegenerative and psychiatric disorders. The company's focus on research and development (R&D) has been a significant expense, which directly impacts the net income, thereby affecting the EPS. In 2023, the company continued its clinical trials for AL001 and ALZN002, which are critical to the development of its therapeutic products. The completion of these trials and the associated costs may have contributed to the stagnant EPS. 2. **Clinical Trial Activities and Expenses**: The company's R&D expenses decreased from $1,908,757 to $447,111 between the same quarter of the previous year, indicating a reduction in clinical trial activities. This decrease in clinical trial activities could suggest that the company may have completed or paused certain trials, which would not contribute to the expense and thus would not impact the EPS negatively as much as ongoing trials would. 3. **Financial Management**: Alzamend Neuro has been managing its financial resources effectively, as evidenced by regaining compliance with Nasdaq listing standards and securing agreements for capital raising, such as the $6.5 million ATM offering. This financial stability allows the company to focus on product development without the burden of financial instability affecting its EPS. In conclusion, Alzamend Neuro's strategic focus on product development and clinical trials, along with effective financial management, has likely contributed to the stagnant EPS in 2023. The company's prioritization of R&D and clinical activities is a sign of its commitment to advancing its therapeutic pipeline, which may not immediately reflect in the EPS but is crucial for long-term growth and potential future revenue streams.